These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 18154762

  • 21. Correspondence.
    Uparkar M, Maiti A, Natarajan S.
    Retina; 2008 Mar; 28(3):527; author reply 527-8. PubMed ID: 18327151
    [No Abstract] [Full Text] [Related]

  • 22. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
    Ng EW, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP.
    Nat Rev Drug Discov; 2006 Feb; 5(2):123-32. PubMed ID: 16518379
    [Abstract] [Full Text] [Related]

  • 23. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration.
    Doggrell SA.
    Expert Opin Pharmacother; 2005 Jul; 6(8):1421-3. PubMed ID: 16013991
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Incidence of ocular hemorrhages in anticoagulated patients receiving repeated intravitreal injections.
    Meyer CH, Eter N.
    Am J Ophthalmol; 2008 Feb; 145(2):386-7. PubMed ID: 18222195
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
    Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM.
    Retina; 2006 Feb; 26(9):994-8. PubMed ID: 17151485
    [Abstract] [Full Text] [Related]

  • 28. Inhibitors of ocular neovascularization: promises and potential problems.
    van Wijngaarden P, Coster DJ, Williams KA.
    JAMA; 2005 Mar 23; 293(12):1509-13. PubMed ID: 15784876
    [No Abstract] [Full Text] [Related]

  • 29. Pegaptanib (Macugen): treating neovascular age-related macular degeneration and current role in clinical practice.
    Vavvas D, D'Amico DJ.
    Ophthalmol Clin North Am; 2006 Sep 23; 19(3):353-60. PubMed ID: 16935210
    [Abstract] [Full Text] [Related]

  • 30. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.
    Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, Goldbaum M, Katz B, Guyer D.
    Br J Ophthalmol; 2008 Dec 23; 92(12):1606-11. PubMed ID: 18614570
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Intravitreal bevacizumab for filtering surgery.
    Jonas JB, Spandau UH, Schlichtenbrede F.
    Ophthalmic Res; 2007 Dec 23; 39(2):121-2. PubMed ID: 17284939
    [Abstract] [Full Text] [Related]

  • 33. Multifocal electroretinography in patients with exudative amd and intravitreal treatment with pegaptanib sodium.
    Lipski A, Bornfeld N, Jurklies B.
    Retina; 2007 Sep 23; 27(7):864-72. PubMed ID: 17891010
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
    VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupCentre for Vision Sciences, The Queen's University of Belfast and The Royal Victoria Hospital, Belfast, United Kingdom., Chakravarthy U, Adamis AP, Cunningham ET, Goldbaum M, Guyer DR, Katz B, Patel M.
    Ophthalmology; 2006 Sep 23; 113(9):1508.e1-25. PubMed ID: 16828500
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin).
    Falkenstein IA, Cheng L, Freeman WR.
    Retina; 2007 Oct 23; 27(8):1044-7. PubMed ID: 18040242
    [Abstract] [Full Text] [Related]

  • 38. Anti-Vascular Endothelial Growth Factor Injection for Exudative Age-related Macular Degeneration in Patients with Vitreo-Macular Traction.
    Querques G.
    Am J Ophthalmol; 2009 Feb 23; 147(2):375-6; author reply 376-7. PubMed ID: 19166716
    [No Abstract] [Full Text] [Related]

  • 39. Macugen treatment for wet age-related macular degeneration.
    Tobin KA.
    Insight; 2006 Feb 23; 31(1):11-4. PubMed ID: 16817567
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.